MTNB logo

MTNB Stock Overview

Profile

Full Name:

Matinas BioPharma Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 21, 2014

Indexes:

Not included

Description:

Matinas BioPharma Holdings (MTNB) is a biopharmaceutical company focused on developing innovative therapies for serious diseases. They specialize in lipid-based drug delivery systems to improve the effectiveness and safety of existing medications, aiming to enhance patient outcomes in various medical conditions.

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 3, 2024

Analyst ratings

Recent major analysts updates

Oct 31, 24 Maxim Group
Hold
Jan 31, 23 HC Wainwright & Co.
Buy
Aug 13, 20 Aegis Capital
Buy
Jan 27, 20 Piper Sandler
Overweight
Jan 24, 20 SunTrust Robinson Humphrey
Buy
Jun 26, 19 HC Wainwright & Co.
Buy
Jun 26, 19 H.C. Wainwright
Buy
May 17, 19 BTIG Research
Buy
May 17, 19 BTIG
Buy
Feb 11, 19 Roth Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair
MTNB
globenewswire.comFebruary 7, 2025

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025.

Matinas BioPharma Receives NYSE Noncompliance Notice
Matinas BioPharma Receives NYSE Noncompliance Notice
Matinas BioPharma Receives NYSE Noncompliance Notice
MTNB
globenewswire.comJanuary 10, 2025

BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
MTNB
globenewswire.comAugust 14, 2024

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
MTNB
Seeking AlphaMarch 28, 2024

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
MTNB
Seeking AlphaNovember 8, 2023

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Penny Stocks To Buy Now? 3 to Watch With Big News
Penny Stocks To Buy Now? 3 to Watch With Big News
Penny Stocks To Buy Now? 3 to Watch With Big News
MTNB
PennyStocksNovember 7, 2023

Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.

Matinas BioPharma to Present at Two Investment Conferences in October 2023
Matinas BioPharma to Present at Two Investment Conferences in October 2023
Matinas BioPharma to Present at Two Investment Conferences in October 2023
MTNB
GlobeNewsWireSeptember 28, 2023

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
MTNB
Zacks Investment ResearchMay 10, 2023

Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
MTNB
GlobeNewsWireMay 3, 2023

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

FAQ

  • What is the ticker symbol for Matinas BioPharma Holdings?
  • Does Matinas BioPharma Holdings pay dividends?
  • What sector is Matinas BioPharma Holdings in?
  • What industry is Matinas BioPharma Holdings in?
  • What country is Matinas BioPharma Holdings based in?
  • When did Matinas BioPharma Holdings go public?
  • Is Matinas BioPharma Holdings in the S&P 500?
  • Is Matinas BioPharma Holdings in the NASDAQ 100?
  • Is Matinas BioPharma Holdings in the Dow Jones?
  • When was Matinas BioPharma Holdings's last earnings report?
  • When does Matinas BioPharma Holdings report earnings?
  • Should I buy Matinas BioPharma Holdings stock now?

What is the ticker symbol for Matinas BioPharma Holdings?

The ticker symbol for Matinas BioPharma Holdings is NYSE American:MTNB

Does Matinas BioPharma Holdings pay dividends?

No, Matinas BioPharma Holdings does not pay dividends

What sector is Matinas BioPharma Holdings in?

Matinas BioPharma Holdings is in the Healthcare sector

What industry is Matinas BioPharma Holdings in?

Matinas BioPharma Holdings is in the Biotechnology industry

What country is Matinas BioPharma Holdings based in?

Matinas BioPharma Holdings is headquartered in United States

When did Matinas BioPharma Holdings go public?

Matinas BioPharma Holdings's initial public offering (IPO) was on July 21, 2014

Is Matinas BioPharma Holdings in the S&P 500?

No, Matinas BioPharma Holdings is not included in the S&P 500 index

Is Matinas BioPharma Holdings in the NASDAQ 100?

No, Matinas BioPharma Holdings is not included in the NASDAQ 100 index

Is Matinas BioPharma Holdings in the Dow Jones?

No, Matinas BioPharma Holdings is not included in the Dow Jones index

When was Matinas BioPharma Holdings's last earnings report?

Matinas BioPharma Holdings's most recent earnings report was on Nov 13, 2024

When does Matinas BioPharma Holdings report earnings?

The next expected earnings date for Matinas BioPharma Holdings is Mar 27, 2025

Should I buy Matinas BioPharma Holdings stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions